Disorders of Excessive Somnolence - Chemically induced
Research News and Information

Monday, November 23, 2009

Rotigotine transdermal delivery for the treatment of Parkinson's disease.

27 Feb 2009 BACKGROUND: Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the ... Read more...

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

Feb 2009 OBJECTIVE: To assess the efficacy and tolerability of the nondopaminergic agent XP13512/GSK1838262 in adults with moderate to severe primary restless legs syndrome (RLS). METHODS: Patient Improvements in Vital Outcomes following Treatment in ... Read more...

Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects.

30 Dec 2008 OBJECTIVE: To evaluate the next-day residual effects of the novel hypnotic, gaboxadol, following bedtime dosing in healthy elderly subjects. METHODS: Healthy women (N = 15) and men (N = 10) aged 65-79 years received a single bedtime (22:00 h) dose ... Read more...

Latest indexed articles for 'Disorders of Excessive Somnolence - Chemically induced'

These are the very latest articles for this heading:

• Posaconazole-induced topiramate toxicity. 19 Jul 2009
• An elderly woman with somnolence and transient hemiparesis. 27 Feb 2009
• Rotigotine transdermal delivery for the treatment of Parkinson's disease. 27 Feb 2009
• Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Feb 2009
• Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects. 30 Dec 2008
• Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. 29 Nov 2008
• A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. 9 Jul 2008
• A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. 8 Jul 2008
• The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. 29 Jun 2008
• Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). 22 Jun 2008
• Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. 30 May 2008
• Delayed presentation of an aripiprazole overdose. 30 Mar 2008
• Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. 30 Mar 2008
• The perioperative implications of khat use. 30 Jan 2008
• The video images of sleep attacks in Parkinson's disease. 28 Jan 2008
• Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. 30 Dec 2007
• Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. 30 Dec 2007
• Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. 30 Dec 2007
• The use of atypical antipsychotics in pediatric bipolar disorder. 30 Dec 2007
• Side effects as influencers of treatment outcome. 30 Dec 2007

See a longer list of these articles.

Technical information about 'Disorders of Excessive Somnolence'

Definition: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)

Descriptor UI: D006970

Alternative terms: Disorders of Excessive Somnolence; Excessive Somnolence Disorder; Somnolence Disorder, Excessive; Somnolence Disorders, Excessive; Excessive Somnolence Disorders; Hypersomnolence Disorders; Hypersomnolence Disorder; DOES (Disorders of Excessive Somnolence); DOESs (Disorders of Excessive Somnolence); Hypersomnolence Disorders, Secondary; Hypersomnolence Disorder, Secondary; Secondary Hypersomnolence Disorder; Secondary Hypersomnolence Disorders; Hypersomnolence; Hypersomnolence Disorders, Primary; Hypersomnolence Disorder, Primary; Primary Hypersomnolence Disorder; Primary Hypersomnolence Disorders; Hypersomnia; Hypersomnias; Hypersomnia, Recurrent; Hypersomnias, Recurrent; Recurrent Hypersomnia; Recurrent Hypersomnias;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C10.886.425.800.200; F03.870.400.800.200;

History Note: 2000(1975)